These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 39088137)
1. Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis. Del Corso LM; Mesa Junior CO; Andrade VFC; Fidalski SZK; Boguszewski CL Pituitary; 2024 Oct; 27(5):537-544. PubMed ID: 39088137 [TBL] [Abstract][Full Text] [Related]
2. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly. Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977 [TBL] [Abstract][Full Text] [Related]
3. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly. Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366 [TBL] [Abstract][Full Text] [Related]
4. Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective. Koylu B; Firlatan B; Sendur SN; Oguz SH; Dagdelen S; Erbas T Endocrine; 2023 Mar; 79(3):545-553. PubMed ID: 36318446 [TBL] [Abstract][Full Text] [Related]
5. Acromegaly. Scacchi M; Cavagnini F Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948 [TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery. Taweesomboonyat C; Oearsakul T World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643 [TBL] [Abstract][Full Text] [Related]
10. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832 [TBL] [Abstract][Full Text] [Related]
11. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly. Schwyzer L; Starke RM; Jane JA; Oldfield EH J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276 [TBL] [Abstract][Full Text] [Related]
12. 3D Volumetric Measurements of GH Secreting Adenomas Correlate with Baseline Pituitary Function, Initial Surgery Success Rate, and Disease Control. Tirosh A; Papadakis GZ; Chittiboina P; Lyssikatos C; Belyavskaya E; Keil M; Lodish MB; Stratakis CA Horm Metab Res; 2017 Jun; 49(6):440-445. PubMed ID: 28472827 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and therapeutic outcomes of acromegalic patients with giant growth hormone-secreting pituitary adenomas: a single-center study of 67 cases. Chen M; Duan L; Miao H; Yu N; Yang S; Wang L; Gong F; Yao Y; Zhu H Pituitary; 2023 Dec; 26(6):675-685. PubMed ID: 37847430 [TBL] [Abstract][Full Text] [Related]
14. [Outcome of somatostatin analogue treatment in acromegaly]. Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182 [TBL] [Abstract][Full Text] [Related]
15. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly. Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329 [TBL] [Abstract][Full Text] [Related]
16. Endoscopic Transsphenoidal Approach for Acromegaly with Remission Rates in 401 Patients: 2010 Consensus Criteria. Anik I; Cabuk B; Gokbel A; Selek A; Cetinarslan B; Anik Y; Ceylan S World Neurosurg; 2017 Dec; 108():278-290. PubMed ID: 28887283 [TBL] [Abstract][Full Text] [Related]
17. Aggressive transsphenoidal resection of tumors invading the cavernous sinus in patients with acromegaly: predictive factors, strategies, and outcomes. Nishioka H; Fukuhara N; Horiguchi K; Yamada S J Neurosurg; 2014 Sep; 121(3):505-10. PubMed ID: 25014437 [TBL] [Abstract][Full Text] [Related]
18. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115 [TBL] [Abstract][Full Text] [Related]
19. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395 [TBL] [Abstract][Full Text] [Related]
20. Postoperative GH and Degree of Reduction in IGF-1 Predicts Postoperative Hormonal Remission in Acromegaly. Cardinal T; Collet C; Wedemeyer M; Singer PA; Weiss M; Zada G; Carmichael JD Front Endocrinol (Lausanne); 2021; 12():743052. PubMed ID: 34867787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]